Rectal Cancer
Conditions
Interventions
Control group:Intravenous infusion of placebo (saline)5ml
Experimental group:Intravenous infusion of parecoxibuner 40mg
Sponsors
Beng Medical First Affiliated Hospital
Eligibility
Sex/Gender
All
Age
40 Years to 64 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: American Society of Anesthesiologists (ASA) class I or II; age 40-64 years, gender not limited; Body Mass Index (BMI): 20-30 kg/?; patients to be operated laparoscopically for radical rectal cancer by the same group of surgeons and under the same procedure; patients and/or their authorized delegates agreed and signed the study informed consent form.
Exclusion criteria
Exclusion criteria: Exclusion criteria: Patients with severe combined lesions of other organs (e.g., heart, brain, liver, kidney, etc.) or contraindications related to surgery; patients with colorectal cancer who have developed clinically distant metastases; patients with immune system disorders; patients who have received immunosuppressive drugs, radiation therapy, and neoadjuvant chemotherapy; patients and/or principals who refuse to sign informed consent or are unable to cooperate with the trial study; patients with other oncologic diseases and/or (or) participate in any other type of study; patients with drug allergy and/or serious adverse reactions; patients with a history of perioperative transfusion and/or resuscitation; patients with long-term use of hormones, analgesic and sedative drugs; patients with mental abnormalities or uncooperable.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CXCL8;CXCR1;CXCR2; | — |
Secondary
| Measure | Time frame |
|---|---|
| IL-6;TNF-?; | — |
Countries
China
Contacts
Public ContactWURUOJIE
The First Affiliated Hospital of Bengbu Medical College
Outcome results
None listed